N^α-Formyllysin | 70671-57-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N^α-Formyllysin
• 英文别名: Formyllysine；6-amino-2-formamidohexanoic acid
• CAS: 70671-57-7
• 化学式: C₇H₁₄N₂O₃
• 分子量: 174.2
• InChiKey: LIEIRDDOGFQXEH-UHFFFAOYSA-N

物化性质

• 沸点：
  434.6±40.0 °C(Predicted)
• 密度：
  1.169±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Flavour Modifying Compounds
  申请人：Givaudan S. A.

  公开号：US20140127144A1

  公开（公告）日：2014-05-08

  A compound of formula (I) is used to modify the taste or flavour of a flavour composition or consumable product, wherein R 1 is H, or a substituted, unsubstituted, branched or unbranched C 1 -C 5 alkyl group and, NHR 2 is a residue of an amino acid, is selected from Alanine (Ala), cysteine (Cys), Aspartic acid (Asp), phenylalanine (Phe), glutamic acid (Glu), histidine (His), isoleucine (Ile), lysine (Lys), leucine (Leu), methionine (Met), asparagines (Asn), glutamine (Gln), arginine (Arg), serine (Ser), theronine (Thr), valine (Val), tryptophan (Trp), tyrosine(Tyr) and Glycine (Gly), with the proviso that the compound is not N-acetyl glycine. Also disclosed are flavour compositions and consumable products containing such compounds.

  化合物的化学式（I）用于改变风味组合物或可食用产品的味道或风味，其中R1是H，或者是取代的、未取代的、支链的或非支链的C1-C5烷基基团，NHR2是氨基酸残基，选自丙氨酸（Ala）、半胱氨酸（Cys）、天冬氨酸（Asp）、苯丙氨酸（Phe）、谷氨酸（Glu）、组氨酸（His）、异亮氨酸（Ile）、赖氨酸（Lys）、亮氨酸（Leu）、蛋氨酸（Met）、天冬酰胺（Asn）、谷氨酰胺（Gln）、精氨酸（Arg）、丝氨酸（Ser）、苏氨酸（Thr）、缬氨酸（Val）、色氨酸（Trp）、酪氨酸（Tyr）和甘氨酸（Gly），但该化合物不是N-乙酰甘氨酸。还公开了含有这种化合物的风味组合物和可食用产品。
• Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention
  申请人：——

  公开号：US20020111291A1

  公开（公告）日：2002-08-15

  Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a contributing cause of diabetic complications. Also disclosed are therapeutic methods of using such inhibitors to reduce formation of AGE-proteins and thereby lessen, reduce and delay diabetic complications and the effects of glycogen storage diseases, including Fanconi's syndrome. Methods for assessing a diabetic's risk of developing complications and for determining the efficacy of the disclosed inhibitor therapy by measuring the ratio of 3DG to 3DF in a biological sample following an oral dose of a fructose-lysine-containing food product are also disclosed.

  本文披露了一类化合物，可以抑制酶催化将果糖赖氨酸转化为果糖赖氨酸-3-磷酸酯的反应，这是一种新发现的代谢途径中依赖ATP的反应。根据该途径的正常功能，果糖赖氨酸-3-磷酸酯（FL3P）被分解为游离赖氨酸、无机磷酸盐和3-脱氧葡萄糖酮（3DG），后者是一种具有反应性的蛋白质修饰剂。3DG可以通过还原为3-脱氧果糖（3DF）来解毒，也可以与内源蛋白质反应形成高级糖基化终产物修饰的蛋白质（AGE-蛋白），据信这是糖尿病并发症的一个促发因素。此外，还披露了使用这种抑制剂的治疗方法，以减少AGE-蛋白的形成，从而减轻、减少和延迟糖尿病并发症和糖原贮积病（包括范科尼综合征）的影响。还披露了通过在口服含果糖赖氨酸的食品后测量生物样品中3DG与3DF比值来评估糖尿病患者发生并发症的风险和确定披露的抑制剂疗法的疗效的方法。
• COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA
  申请人：McClay Allen

  公开号：US20090047221A1

  公开（公告）日：2009-02-19

  There is described compounds for use in therapy, said compounds being defined by Formula (1): There is also described an anti-proliferative composition comprising one or more compounds according to Formula (1), and a method of treatment of neoplasia comprising the administration of such a compound or composition.

  本文描述了用于治疗的化合物，该化合物由公式（1）定义：还描述了一种抗增殖组合物，其中包括一个或多个符合公式（1）的化合物，以及一种治疗肿瘤的方法，包括给予这样的化合物或组合物。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS
  申请人：CIDARA THERAPEUTICS, INC

  公开号：US20160213742A1

  公开（公告）日：2016-07-28

  Compositions and methods for the treatment of fungal infections including compounds containing a pathogen pattern recognition receptor ligand and a β 1,3-glucan synthase inhibitor are disclosed. In particular, compounds containing a lipopeptide moiety and a formyl peptide receptor ligand can be used in the treatment of fungal infections caused by a fungus of the genus Aspergillus or Candida.

  本发明涉及用于治疗真菌感染的组合物和方法，其中包括含有病原体模式识别受体配体和β 1,3-葡聚糖合成酶抑制剂的化合物。特别地，含有脂肽基团和甲酰肽受体配体的化合物可用于治疗由曲霉属或白色念珠菌属真菌引起的真菌感染。
• Molecular vaccines for infectious disease
  申请人：Schøller Jørgen

  公开号：US10369204B2

  公开（公告）日：2019-08-06

  The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals.

  本发明涉及构建药剂的方法，即以其多聚化结构域和所附生物活性分子为特征的疫苗成分，以及将其用于制备单独含有药剂或与其他分子结合的疫苗。构建体的各个分子可以通过共价键或非共价键，直接或通过连接体相互结合或与多聚化结构域结合。本发明进一步涉及此类制剂在疫苗中的使用，旨在作为人类和动物的预防/预防性或治疗性疫苗。